Information Disclosure! Fuyuan Pharmaceutical, Shuanglin Co., Ltd., Buchang Pharmaceutical and other companies made important announcements
Fuguan Pharmaceutical: Cilostazol Tablets Obtain Registration Certificate] Fukuan Pharmaceuticals: Cilostazol Tablets Receive Registration Certificate] Fuguan Pharmaceutical: Cilostazol Tablets Obtain Registration Certificate.
Fuyuan Pharmaceutical announced that the company's drug cilostazol tablets have obtained the drug registration certificate. As of the date of this announcement, the Company's cumulative investment in the research and development of this drug is RMB 5 458 700 (unaudited).
Shuanglin shares: share repurchase worth 30 million to 60 million yuan]. ］
Shuanglin Co., Ltd. announced that it intends to repurchase shares worth 30 million yuan to 60 million yuan, and repurchase no more than (including) 12 yuan shares.
Flanders earnings update: 2023 net profit up 3678%]。
Furun Co., Ltd. released a performance report, achieving a total operating income of 97 in 20237.9 billion yuan, down 544%；Net profit 41.7 billion yuan, a year-on-year increase of 3678%；Basic earnings per share was 084 yuan. During the reporting period, the company's sales to end users increased compared with the same period last year, and the gross profit margin of sales to end users was higher, so the company's net profit in 2023 increased more than the same period last year.
Buchang Pharmaceutical: Clinical trial approval of BC001, an accessory drug for injection] - Buchang Pharmaceutical: Clinical trial approval of BC001, an accessory drug for injection.
Buchang Pharmaceuticals announced that a subsidiary of its parent company has received IND approval for BC001, an injectable drug, to use BC001 in combination with a monoclonal antibody PD-1 in advanced or metastatic solid tumors.
onlikon: the subsidiary obtained the approval number of veterinary drug products].
Recently, Agricultural Bank of China Co., Ltd. obtained the veterinary drug issued by the Ministry of Agriculture and Rural Affairs"Cimetidine tablets (for pets)."Approval documents.
HYSCO: Approved for clinical trial of innovative drug HSK39775 tablets
Haisco announced that its subsidiary, Haisco Pharmaceutical, has obtained the clinical trial approval notice for the innovative drug HSK39775 tablets.
The content of this article is public information based on statistical data and does not constitute advice or a basis for buying or selling.